We believe that we are the first medical laboratory in the US to provide this genetic testing support that provides results the ‘same-day’ a bloodstream specimen is received.. Clinical testing service for safer dosing of warfarin Machaon Diagnostics, California’s only independent laboratory for tests bleeding and clotting disorders has launched a clinical assessment service for patients that have been prescribed warfarin. Machaon’s FDA-approved array-based technology detects genetic variants in 2 key genes involved in the rate of metabolism of warfarin. Related StoriesBerkeley Lab scientists identify genetic elements that influence neurological disorders and body weightTesting amniotic fluid could guidebook doctors to create delivery planning decisions for preterm birthsNew scientific trial on breast tumor may help deal with and control diseaseTraditional warfarin dosing is basically based on trial and error.Funding for the study and development plan was provided by both open public and private sources like the MIT Institute for Integrative Center for Tumor Study, the National Institute for Biomedical Bioengineering and Imaging, a prostate malignancy SPORE Grant awarded to Dana-Farber Malignancy Institute, the National Malignancy Institute, the NCI Alliance in Nanotechnology and the Prostate Cancers Foundation. These seminal data on BIND’s first medical stage Accurin, BIND-014, demonstrates for the very first time that it’s possible to generate medications with both targeted and programmable properties that may concentrate the therapeutic impact at the website of disease directly, revolutionizing how complex illnesses such as for example cancer are potentially treated, commented Omid Farokhzad, M.D., BIND Associate and Founder Professor, Harvard Medical College.